ClinConnect ClinConnect Logo
Search / Trial NCT02247297

Pancreatic Stone Protein (PSP) in Pregnant Women

Launched by NICOLE OCHSENBEIN · Sep 18, 2014

Trial Information

Current as of June 28, 2025

Unknown status

Keywords

Pancreatic Stone Protein (Psp) Premature Rupture Of Membranes (Pprom) Amniotic Infection Syndrome (Ais) Hemolysis, Elevated Liver Enzymes, And Low Platelets (Hellp) Preeclampsia Pregnancy

ClinConnect Summary

Pregnant women feature a complex immunological condition caused by pregnancy itself and hence women present with an increased susceptibility to some infectious and non-infectious inflammatory diseases. Specifically regulated mechanisms have been described occurring in normal whereas lacking in pathological pregnancies in both the native and adaptive immune system in animal models and humans. However, clinically relevant biomarker associated with preterm premature rupture of membranes (PPROM), amniotic infection syndrome (AIS) as well as pregnancy associated complications such as preeclampsi...

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Age \> 18 years
  • Healthy women with single pregnancy
  • Women with PPROM, AIS, preeclampsia, or HELLP syndrome
  • Patients able to provide informed consent
  • Exclusion Criteria:
  • Viral (hepatitis B virus, hepatitis C virus, human immunodeficiency virus) or confirmed bacterial infections

About Nicole Ochsenbein

Nicole Ochsenbein is a dedicated clinical trial sponsor known for her commitment to advancing medical research and improving patient outcomes. With a strong background in clinical development and regulatory affairs, she leads initiatives that focus on innovative therapies and treatment modalities across various therapeutic areas. Nicole collaborates closely with researchers, healthcare professionals, and regulatory bodies to ensure the integrity and efficacy of clinical trials, fostering an environment of transparency and ethical practices. Her leadership is characterized by a patient-centered approach, emphasizing the importance of participant safety and informed consent throughout the research process.

Locations

Zurich, , Switzerland

Patients applied

0 patients applied

Trial Officials

Nicole Ochsenbein, Prof. Dr.

Principal Investigator

University of Zurich

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials